All In Biotech

Drug Trial Radar · NCT06850922

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema

A Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Patients With Diabetic Macular Edema

Last checked: Nov 19, 2026Latest source record: Jun 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 388 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

388

Actual

Start

Jun 22, 2022

Primary completion

May 19, 2026

Study completion Jun 19, 2026

Sponsor

Lead sponsor
Genentech, Inc.Roche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Feb 28, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to evaluate the ocular and systemic safety, tolerability and efficacy of RO7446603 in participants with diabetic macular edema (DME). The study consists of 2 segments: Phase I (Parts 1-4) and Phase II (Part 5). Phase I investigated the safety of RO7446603 following a single and multiple intravitreal (IVT) doses as monotherapy or co-administered with IVT aflibercept or IVT faricimab (in separate injections). Phase II will investigate the safety, tolerability, pharmacokinetics (PK) and efficacy of two dose levels of RO7446603 in combination with faricimab, with the two drugs co-mixed and administered as a single IVT injection, compared to faricimab alone. The first participant was enrolled in the Phase I segment on June 22, 2022. Phase I has been completed.

Conditions

  • Diabetic Macular Edema

Interventions

  • RO7446603Drug

    Participants will receive RO7446603 as an IVT injection per the schedule described in the treatment arms.

  • AfliberceptDrug

    Participants will receive aflibercept as an IVT injection per the schedule described in the treatment arm.

  • FaricimabDrug

    Participants will receive faricimab as an IVT injection per the schedule described in the treatment arms.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Parts 1-5: Percentage of Participants With Adverse Events (AEs)Time frame: From study start through end of study (Up to approximately 58 months)
  2. Parts 1-5: Percentage of Participants With Ocular AEsTime frame: From study start through end of study (Up to approximately 58 months)
  3. Part 1: Change in Best Corrected Visual Acuity (BCVA) Over TimeTime frame: From Baseline up to Week 16
  4. Parts 2-4: Change in BCVA Over TimeTime frame: From Baseline up to Week 28
  5. Part 5: Change From Baseline in BCVA Averaged Over Weeks 52 and 56Time frame: From Baseline up to Week 56

Locations

77 sites in 3 countries. Site status is shown where the registry gives one.

  • Arizona Retina and Vitreous Consultants

    Phoenix, Arizona

  • Associated Retinal Consultants PC

    Phoenix, Arizona

  • Retinal Research Institute, LLC

    Phoenix, Arizona

  • Retina Partners of Northwest Arkansas, PLLC

    Springdale, Arkansas

  • Retinal Diagnostic Center

    Campbell, California

  • Retina Consultants of Orange County

    Fullerton, California

  • Retinal Consultants Medical Group

    Modesto, California

  • Northern California Retina-Vitreous Associates

    Mountain View, California

  • Retinal Consultants Medical Group

    Sacramento, California

  • University of California San Francisco

    San Francisco, California

  • Macula Retina Vitreous Research Institute

    Torrance, California

  • Bay Area Retina Associates;Study Department

    Walnut Creek, California

  • University of Colorado - Eye Center - PPDS

    Aurora, Colorado

  • Retina Consultants of Southern Colorado PC

    Colorado Springs, Colorado

  • Retina Specialists of Colorado

    Denver, Colorado

  • Advanced Vision Research Institute

    Longmont, Colorado

  • Retina Group of New England

    Waterford, Connecticut

  • National Ophthalmic Research Institute

    Fort Myers, Florida

  • Florida Retina Institute

    Jacksonville, Florida

  • Retina Associates of Florida;Retina Associates of Florida

    Tampa, Florida

  • Southeast Retina Center

    Augusta, Georgia

  • Georgia Retina PC

    Marietta, Georgia

  • Retina Consultants of Hawaii

    ‘Aiea, Hawaii

  • Illinois Eye and Ear Infirmary

    Chicago, Illinois

  • University Retina and Macula Associates, PC

    Oak Forest, Illinois

  • Raj K. Maturi, MD PC

    Indianapolis, Indiana

  • The Retina Care Center

    Baltimore, Maryland

  • Johns Hopkins Hospital

    Baltimore, Maryland

  • Retina Group of Washington

    Chevy Chase, Maryland

  • Cumberland Valley Retina Consultants

    Hagerstown, Maryland

  • Chesapeake Retina Centers - Waldorf

    Waldorf, Maryland

  • Associated Retinal Consultants - Royal Oak

    Royal Oak, Michigan

  • Retina Consultants Minnesota

    Saint Louis Park, Minnesota

  • Long Island Vitreoretinal Consultants;Opthalmology

    Hauppauge, New York

  • Retina Vitreous Surgeons of CNY PC

    Liverpool, New York

  • Opthalmic Consultants of LI

    Lynbrook, New York

  • Western Carolina Retinal Associate PA

    Asheville, North Carolina

  • North Carolina Retina Associates

    Cary, North Carolina

  • Duke University Medical Center

    Durham, North Carolina

  • Graystone Eye-Hickory

    Hickory, North Carolina

Showing 40 of 77 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.